Merck & Co. vs GE HealthCare
Side-by-side comparison of AI visibility scores, market position, and capabilities
Global pharma anchored by Keytruda ($25B cancer drug); $63.6B FY2024 revenue; Gardasil China collapse 2024 ($2B loss); Winrevair PAH approval 2024; Keytruda patent cliff 2028-2030 is defining challenge.
About
Merck & Co. is one of the world's largest research-driven pharmaceutical companies, founded in the United States in 1891 as a subsidiary of the German Merck KGaA and now an independent American company headquartered in Rahway, New Jersey, trading on NYSE (MRK). The company generated approximately $63.6 billion in revenues for FY2024 under CEO Robert Davis, anchored by Keytruda (pembrolizumab)—the world's best-selling cancer drug—which generated approximately $25 billion in global sales as the dominant checkpoint inhibitor immunotherapy across over 40 approved tumor indications including lung cancer, melanoma, bladder cancer, cervical cancer, and dozens more. Merck's animal health subsidiary, Merck Animal Health, is a global leader in livestock and companion animal medicines including Bravecto (flea/tick prevention) and contributes approximately $6 billion in revenues.
Chicago medical imaging and AI diagnostics (NASDAQ: GEHC) ~$19.7B FY2024 revenue; GE spinoff Jan 2023, Edison AI 100+ models, 4M+ installed devices, Alzheimer's PET tracer competing with Siemens Healthineers.
About
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designing, manufacturing, and servicing medical imaging systems, patient monitoring equipment, pharmaceutical diagnostics, and AI-powered clinical decision support software through approximately 51,000 employees in 160 countries. GE HealthCare was spun off from General Electric Company in January 2023 — one of the most significant healthcare demergers in history — and has operated as an independent public company building its own capital structure, R&D investment priorities, and operational identity separate from GE's industrial conglomerate structure. In fiscal year 2024, GE HealthCare reported revenues of approximately $19.7 billion, with its four business segments contributing: Imaging (MRI, CT, X-ray, molecular imaging — ~$9.1B), Ultrasound (~$3.0B), Patient Care Solutions (monitoring, anesthesia — ~$3.6B), and Pharmaceutical Diagnostics (PET/SPECT contrast agents — ~$2.6B). CEO Peter Arduini has prioritized accelerating GE HealthCare's AI integration across its imaging portfolio — the Edison AI platform (100+ AI models cleared or in development for radiology workflows) embeds AI-assisted detection, workflow optimization, and image quality enhancement into GE HealthCare scanners, positioning the company as a digital health platform rather than a hardware manufacturer.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.